The relationship between chronic obstructive pulmonary disease (COPD ... including diagnostic criteria and management of acute exacerbation of CB (AECB) in the elderly patient.

Exacerbations of COPD are common and ... for 7–10 days recommended in current guidelines. Chronic obstructive pulmonary disease (COPD) is a condition of chronic airflow limitation that is ...

The following is a summary of “Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a ...

Benralizumab is more effective than prednisolone in treating eosinophilic exacerbations in patients with asthma and COPD.

In asthma, lower end-tidal carbon dioxide may predict acute exacerbation outcomes, although other measures may be better severity indicators.

Pegtarazimod is under clinical development by ReAlta Life Sciences and currently in Phase I for Coronavirus Disease 2019 (COVID-19) Associated Acute Lung Injury.

Clinical trial results have shown that a drug called benralizumab is effective at treating acute attacks of both asthma and chronic obstructive pulmonary disease (COPD), and it works better than ...

IL-5 is a key cytokine (protein) in type 2 inflammation, an inflammatory process exhibited in up to 40% of patients with COPD and the underlying pathobiology that drives symptoms and exacerbations ...